Iclaprim
| Clinical data | |
|---|---|
| Routes of administration | intravenous |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.130.860 |
| Chemical and physical data | |
| Formula | C19H22N4O3 |
| Molar mass | 354.410 g·mol−1 |
| 3D model (JSmol) | |
| Chirality | Racemic mixture |
| |
| |
| (what is this?) (verify) | |
Iclaprim is an antibiotic drug candidate that is active against Gram positive organisms. It is administered intravenously.: 3
In vitro, iclaprim is active against methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Staphylococcus aureus (VRSA), strains of Streptococcus pneumoniae resistant to several common antibiotics, and some Gram-negative bacteria. It is of the diaminopyrimidine dihydrofolate reductase (DHFR)-inhibiting type.